Effect of smoking status on the efficacy of the SMART regimen in high risk asthma

Respirology

Volumn 21, Issue 5, 2016, Pages 858-866

  Pilcher, Janine ^a,b   Patel, Mitesh ^a,b,c   Reddel, Helen K ^d   Pritchard, Alison ^a   Black, Peter ^e   Shaw, Dominick ^c   Holt, Shaun ^f   Weatherall, Mark ^b,g   Beasley, Richard ^a,b  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f Clinicanz   (New Zealand)

^g UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

adult; asthma; medication adherence; randomized controlled trial; smoking

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; SALBUTAMOL;

ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; SMOKING; TREATMENT OUTCOME;

EID: 84975091181     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12740     Document Type: Article

References (28)

1. Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur. Respir. J. 2013; 41: 716–26.
2. Thomson NC, Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr. Opin. Pulm. Med. 2009; 15: 39–45.
3. Shavit O, Swern A, Dong Q, Newcomb K, Sazonov Kocevar V, Taylor SD. Impact of smoking on asthma symptoms, healthcare resource use, and quality of life outcomes in adults with persistent asthma. Qual. Life Res. 2007; 16: 1555–65.
4. Patel SN, Tsai CL, Boudreaux ED, Kilgannon JH, Sullivan AF, Blumenthal D, Camargo CA Jr. Multicenter study of cigarette smoking among patients presenting to the emergency department with acute asthma. Ann. Allergy Asthma Immunol. 2009; 103: 121–7.
5. Mitchell I, Tough SC, Semple LK, Green FH, Hessel PA. Near-fatal asthma: a population-based study of risk factors. Chest 2002; 121: 1407–13.
6. Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest 1995; 108: 10–5.
7. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, Aldington S, Beasley R. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007; 62: 219–23.
8. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57: 226–30.
9. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Deykin A, DiMango E, Fish JE, Ford JG et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am. J. Respir. Crit. Care Med. 2007; 175: 783–90.
10. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005; 60: 282–7.
11. Pedersen B, Dahl R, Karlstrom R, Peterson CG, Venge P. Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am. J. Respir. Crit. Care Med. 1996; 153: 1519–29.
12. Pedersen SE, Bateman ED, Bousquet J, Busse WW, Yoxall S, Clark TJ. Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the gaining optimal asthma control study. J. Allergy Clin. Immunol. 2007; 120: 1036–42.
13. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am. J. Respir. Crit. Care Med. 2003; 168: 1308–11.
14. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744–53.
15. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med. 2005; 171: 129–36.
16. Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir. Med. 2013; 1: 23–31.
17. Patel M, Pilcher J, Pritchard A, Perrin K, Travers J, Shaw D, Holt S, Harwood M, Black P, Weatherall M et al. Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir. Med. 2013; 1: 32–42.
18. Patel M, Pilcher J, Chan A, Perrin K, Black P, Beasley R. Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: Implications for asthma clinical trial use. J. Allergy Clin. Immunol. 2012; 130: 1420–2.
19. Patel M, Pilcher J, Travers J, Perrin K, Shaw D, Black P, Weatherall M, Beasley R. Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. J Allergy Clin. Immunol. Pract. 2013; 1: 83–91.
20. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 2009; 180: 59–99.
21. Symbicort SMART Asthma Action Plan. (National Asthma Council Australia). From http://www.nationalasthma.org.au/health-professionals/tools-for-primary-care/asthma-action-plans/asthma-action-plan-library. [Accessed 28 June 2012].
22. Holt S, Masoli M, Beasley R. The use of the self-management plan system of care in adult asthma. Prim. Care Respir. J. 2004; 13: 19–27.
23. Balanag VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm. Pharmacol. Ther. 2006; 19: 139–47.
24. Rubinfeld AR, Scicchitano R, Hunt A, Thompson PJ, Van Nooten A, Selross O. Formoterol Turbuhaler as reliever medication in patients with acute asthma. Eur. Respir. J. 2006; 27: 735–41.
25. Aaronson D, Kaiser H, Dockhorn R, Findlay S, Korenblat P, Thorsson L, Kallen A. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study. J. Allergy Clin. Immunol. 1998; 101: 312–9.
26. van Schayck OC, Haughney J, Aubier M, Selroos O, Ekstrom T, Ostinelli J, Buhl R. Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study. Respir. Med. 2012; 106: 189–96.
27. Ministry of Health. Tatau Kahukura: Maori Health Chart Book 2010, 2nd Edn. Ministry of Health, Wellington, 2010.
28. Pilcher J, Patel M, Smith A, Davies C, Pritchard A, Travers J, Black P, Weatherall M, Beasley R, Harwood M. Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Maori with asthma. Respirology 2014; 19: 842–51.